AAV + TRAIL

AAV + TRAIL is a **gene therapy combination** consisting of an **adeno-associated virus (AAV) vector** engineered to deliver the gene encoding **tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L)**. The AAV vector acts as a delivery mechanism, carrying the TRAIL gene into target cells, typically tumor cells, thereby enabling local production of TRAIL and induction of apoptosis in cancer cells. **TRAIL** binds selectively to death receptors on cancer cells to trigger programmed cell death via extrinsic apoptotic pathways, while sparing most normal cells. Preclinical studies have demonstrated potent antitumor efficacy, including tumor growth suppression and improved survival in various mouse models of cancers such as lymphoma, hepatocellular carcinoma, lung adenocarcinoma, and head and neck squamous cell carcinoma. Engineered variants include cell-selective promoters (e.g., hTERT for cancer targeting) and soluble TRAIL forms. Overcoming TRAIL resistance is a notable focus, with combination approaches, such as co-delivery of TRAIL-sensitizing elements (e.g., miR-221-Zip), enhancing effectiveness in resistant tumors[1][2].

Other names

adeno-associated virus encoding TRAILAAV-TRAILAAV2-TRAILAAV-2-TRAILAAV 2-TRAILAAV2-sTRAILAAV-2-sTRAILAAV 2-sTRAILAAV2-hTERT-TRAILAAV-2-hTERT-TRAILAAV 2-hTERT-TRAIL